ERBB2 and breast cancer: Liu [41] found that delayed chemotherapy did not increase the risk of recurrence in patients with luminal A breast cancer, but delayed chemotherapy in patients with luminal B, triple-negative, or HER2-positive breast cancer without trastuzumab treatment reduced the five-year DFS.